Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesWork In Process
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

CV Sciences (CVSI) Liabilities and Shareholders Equity (2016 - 2025)

CV Sciences' Liabilities and Shareholders Equity history spans 14 years, with the latest figure at $7.0 million for Q3 2025.

  • For Q3 2025, Liabilities and Shareholders Equity fell 16.64% year-over-year to $7.0 million; the TTM value through Sep 2025 reached $30.6 million, down 12.33%, while the annual FY2024 figure was $7.9 million, 13.84% down from the prior year.
  • Liabilities and Shareholders Equity for Q3 2025 was $7.0 million at CV Sciences, down from $8.0 million in the prior quarter.
  • Across five years, Liabilities and Shareholders Equity topped out at $30.7 million in Q1 2021 and bottomed at $7.0 million in Q3 2025.
  • The 5-year median for Liabilities and Shareholders Equity is $9.9 million (2023), against an average of $13.6 million.
  • The largest annual shift saw Liabilities and Shareholders Equity plummeted 43.34% in 2022 before it fell 8.33% in 2025.
  • A 5-year view of Liabilities and Shareholders Equity shows it stood at $18.1 million in 2021, then decreased by 29.5% to $12.7 million in 2022, then dropped by 27.76% to $9.2 million in 2023, then dropped by 13.84% to $7.9 million in 2024, then fell by 11.76% to $7.0 million in 2025.
  • Per Business Quant, the three most recent readings for CVSI's Liabilities and Shareholders Equity are $7.0 million (Q3 2025), $8.0 million (Q2 2025), and $7.8 million (Q1 2025).